The Chemours Company (NYSE:CC) Stock Has Consensus Target Price of $17.73

Shares of The Chemours Company (NYSE:CC) have been given a consensus recommendation of “Hold” by the thirteen ratings firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $17.36.

Several research analysts have recently commented on the company. Barclays started coverage on Chemours in a research note on Monday, October 12th. They set an “equal weight” rating and a $16.00 target price for the company. Truist Financial dropped their price target on Chemours from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Chemours in a report on Tuesday, November 3rd. Royal Bank Of Canada cut shares of Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price objective for the company. in a research report on Tuesday, October 13th. Finally, BMO Capital Markets decreased their price objective on shares of Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th.

Chemours Stock Up 1.4%

NYSE CC opened at $13.46 on Wednesday. The stock has a fifty day moving average of $13.87 and a 200-day moving average of $18.19. Chemours has a 52 week low of $10.44 and a 52 week high of $28.67. The stock has a market capitalization of $2.03 billion, a P/E ratio of -13.20 and a beta of 1.47. The company has a debt-to-equity ratio of 24.25, a quick ratio of 0.98 and a current ratio of 1.81.

Chemours (NYSE:CC) last announced its quarterly earnings data on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). Chemours had a positive return on equity of 76.52% and a negative net margin of 2.64%. The company had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the prior year, the company earned $0.40 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. On average, equities research analysts forecast that Chemours will post 0.82 EPS for the current year.

Chemours Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be given a $0.0875 dividend. The ex-dividend date of this dividend is Monday, November 16th. This represents a $0.35 annualized dividend and a dividend yield of 2.6%. Chemours’s dividend payout ratio is presently -34.31%.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Stronger titanium dioxide pricing and growth in Advanced Performance Materials (APM) partly offset weak Thermal & Specialized Solutions (TSS) volumes in the third quarter. Zacks Q3 earnings report
• Negative Sentiment: Multiple law firms publicized a securities class action filed against Chemours and certain officers. The suit covers investors who acquired shares from February 20 through August 4, 2026, and alleges that the company misrepresented or failed to disclose weakening Opteon aftermarket demand while reaffirming its 2026 outlook. These are allegations, not established findings; the lead-plaintiff deadline is December 7. The litigation adds legal and reputational risk. Pomerantz class action announcement
• Negative Sentiment: Chemours’ third-quarter EPS of $0.21 fell short of the $0.26 analyst consensus, with weak TSS volumes weighing on results, despite revenue slightly exceeding expectations. Zacks Q3 earnings report
• Negative Sentiment: JPMorgan lowered its price target from $15 to $14 and maintained a Neutral rating, signaling more limited expected upside. JPMorgan rating information

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Chemours during the second quarter valued at $477,769,000. Wolf Hill Capital Management LP acquired a new position in shares of Chemours during the second quarter worth $59,698,056. Jefferies Financial Group Inc. grew its stake in shares of Chemours by 251.8% in the third quarter. Jefferies Financial Group Inc. now owns 2,742,068 shares of the specialty chemicals company’s stock worth $37,210,000 after purchasing an additional 1,962,523 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Chemours in the second quarter worth $33,353,000. Finally, Bank of America Corp DE grew its stake in shares of Chemours by 79.1% in the first quarter. Bank of America Corp DE now owns 1,317,003 shares of the specialty chemicals company’s stock worth $29,014,000 after purchasing an additional 581,621 shares during the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Company Profile

The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours’ Titanium Technologies business makes titanium dioxide (TiO₂) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.